Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
CRU sees EU carbon price rising in August on higher power demand, weak wind output

CRU sees EU carbon price rising in August on higher power demand, weak wind output

ReutersReuters2026/08/04 18:59
  • CRU forecast EU carbon prices rising in August on higher power demand, weaker wind output, subdued nuclear generation.
  • EUAs ended July near € 81/tCO₂, broadly matching CRU’s ~€ 80/tCO₂ call as wind improved m/m but stayed below norms.
  • EU ETS review sparked a brief rally, then reversed as proposals removed automatic MSR cancellations above 400 million surplus allowances.
  • CRU base case sees no meaningful gas-to-coal switching in August as gas, coal prices are expected to fall comparatively.
  • Above-average temperatures are projected to lift cooling demand, tightening power-market fundamentals even without fuel-switching support.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRU International Limited published the original content used to generate this news brief on July 31, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma

GlaxoSmithKline announced on Tuesday that it has reached an agreement with Chinese biotechnology company ImmuneOnco to acquire the global rights to one of the latter’s trispecific T-cell engagers (TCE) for a total transaction amount of up to $750 million.

智通财经2026/09/15 08:06
GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma